9/105 sources · 5 publishersUpdated Oct 8, 14:06 UTC
Novartis agrees Abogen RNA therapy licensing deal worth up to $7.8bn
Novartis agreed to license worldwide rights to Abogen Biosciences' investigational autoimmune therapy ABO2203 and secured options on further RNA-platform programs. The agreement is worth up to $7.8bn, including a $575m upfront payment and potential development, regulatory and commercial payments. Closing remains contingent on customary conditions and regulatory clearances.
Why it matters
The deal gives Novartis an mRNA-based autoimmune candidate and option rights to additional Abogen programs. Its financial exposure beyond the upfront payment depends on option exercises and the achievement of specified milestones.
Key facts
- 1Novartis will receive worldwide rights to ABO2203 and exclusive options for additional potential therapies using Abogen's RNA platform. biopharmaapac.com
- 2Abogen is set to receive an upfront payment of USD 575 million. biopharmaapac.com
- 3If every option is exercised and agreed conditions are met, Abogen could receive up to approximately USD 7.2 billion in milestone payments. biopharmaapac.com
- 4The transaction requires customary closing conditions, including regulatory clearances. biopharmaapac.com
- 5ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager under development for autoimmune diseases. biopharmaapac.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.